financetom
Business
financetom
/
Business
/
Resource Capital Fund VI Sells Shares of Talon Metals for $29.8 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Resource Capital Fund VI Sells Shares of Talon Metals for $29.8 Million
Sep 22, 2024 11:17 PM

06:22 AM EDT, 09/18/2024 (MT Newswires) -- Resource Capital Fund VI (RCF) late on Tuesday said it had sold 350,000 common shares in Talon Metals Corp. ( TLOFF ) for around $29.8 million, or $0.085 per share.

Before the sale, RCF owned and controlled around 114.9 million Talon shares, representing about 12.3% of the stock.

Talon's share price lost 5.6% to $0.09, near 52-week lows, on Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Live Nation probing Ticketmaster hack amid user data leak concerns
Live Nation probing Ticketmaster hack amid user data leak concerns
Jun 3, 2024
SAN FRANCISCO (Reuters) - Live Nation Entertainment said on Friday it was investigating a data breach at its Ticketmaster unit that it discovered on May 20, the latest in a string of high-profile corporate hacks in the past year. In a filing with the U.S. Securities and Exchange Commission, Live Nation said it found unauthorized activity in a third-party cloud...
Boeing executives unlikely to be charged over 737 MAX crashes, source says
Boeing executives unlikely to be charged over 737 MAX crashes, source says
Jun 3, 2024
New York (Reuters) - Boeing ( BA ) executives are unlikely to be criminally charged over fatal crashes in 2018 and 2019 that killed 346 people as the statute of limitations has likely passed, U.S. Justice Department officials told victims' family members in a meeting. Details were corroborated by a person familiar with the gathering on Friday and correspondence reviewed...
Intellia Therapeutics' NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate
Intellia Therapeutics' NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate
Jun 3, 2024
05:22 AM EDT, 06/03/2024 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Sunday that it observed a 98% mean reduction in monthly attack rate in the phase 1 portion of its ongoing phase 1/2 study of NTLA-2002. The study is evaluating the safety and activity of NTLA-2002 in adults with Type I or Type II hereditary angioedema, or HAE,...
GSK Interim Analysis of Phase III Trial for Blood Cancer Therapy Shows Promise
GSK Interim Analysis of Phase III Trial for Blood Cancer Therapy Shows Promise
Jun 3, 2024
05:18 AM EDT, 06/03/2024 (MT Newswires) -- GSK (GSK) said on Sunday that an interim analysis of the phase III trial evaluating its experimental therapy belantamab mafodotin, in combination with pomalidomide plus dexamethasone, showed promise as a second-line and later treatment for a type of blood cancer. The study showed statistically significant and clinically meaningful improvement in progression-free survival for...
Copyright 2023-2025 - www.financetom.com All Rights Reserved